MMP9 and neoplasm: DOX was linked on the adjuvants-core with a substrate peptide of matrix metalloproteinase 9 (sMMP9), a TME-responsive peptide, to ensure that DOX could effectively release in TME to kill tumor cells and simultaneously generate tumor-specific antigens upon the nanoparticles reached in tumor tissue, meanwhile, the MPLA-CpG SNA core could high-efficiently boost the ICD-induced tumor-specific personalized immune response to further attack tumor cells improving the antitumor efficacy (Scheme 1).